Novanta Inc. (NOVTU) 股票分析

公司概述

Novanta Inc. operates as a comprehensive provider of precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions within both the United States and international markets. The company is categorized within the Technology sector and specifically functions in the Scientific & Technical Instruments industry, positioning it at the intersection of advanced engineering and healthcare infrastructure. In terms of scale, the company employs approximately 3,000 individuals across its operations, though specific market capitalization data is currently unavailable for public reporting. The reported trailing twelve-month revenue of $980.60M, combined with the lack of a disclosed market cap, indicates a substantial operational footprint driven by significant annual sales rather than traditional equity valuation multiples.

财务健康

Novanta Inc. reported a trailing twelve-month revenue of $980.60M and generated $53.83M in net income, while achieving an EBITDA of $178.03M. The substantial disparity between the $980.60M revenue and the $53.83M net income highlights a distinct cost structure where operating expenses and taxes consume the majority of gross earnings before reaching the bottom line. The company maintains a free cash flow of $64.27M, which provides a critical measure of financial flexibility for capital allocation and operational resilience. Profitability is further contextualized by a gross margin of 44.4%, an operating margin of 11.7%, and a profit margin of 5.5%, illustrating that while the company retains nearly half of its sales as gross profit, significant costs remain before arriving at the final net profit. On the balance sheet, the company holds $380.87M in cash against $302.74M in debt, resulting in a debt-to-equity ratio of 23.03. This specific debt-to-equity figure suggests a leveraged position where debt significantly outweighs equity, yet the current ratio of 3.69 indicates robust short-term liquidity capable of covering obligations multiple times over. Return on Equity stands at 5.2% and return on assets is 4.5%, metrics that reveal the efficiency of management in generating returns from shareholder equity and total assets, respectively.

估值评估

The P/E Ratio (TTM) and Forward P/E are both listed as N/A, suggesting that either the stock trades without a standard trailing earnings multiple or that earnings data used for these specific metrics is not currently available for standard calculation. Similarly, the Price to Sales ratio is N/A, while the EV/EBITDA stands at 10.21, providing an enterprise value multiple that suggests the market is valuing the company's earnings before interest, taxes, depreciation, and amortization at roughly ten times its current level. The Price to Book ratio is 1.44, indicating that the market values the company at 44% above its net asset book value, reflecting a premium assigned to its intangible assets or future growth potential within the scientific instruments sector. Regarding price volatility, the 52-week high is recorded at $64.51 and the 52-week low at $47.57. Without a specific current trading price provided in the available facts, the precise percentage position relative to this range cannot be calculated, but the spread between the high and low defines the recent trading band. The beta is 1.65, which signifies that the stock price is expected to exhibit 65% higher volatility than the broader market, implying that price movements will likely be amplified relative to general market index fluctuations.

Growth & Income

The company experienced a revenue growth rate of 8.5% year-over-year, whereas earnings growth registered at 0.6% for the same period. This divergence indicates that earnings are growing at a significantly slower pace than revenue, implying that the expansion in sales has not yet been fully translated into proportional bottom-line profitability, likely due to the high fixed cost structure or margin compression. As the data shows a Dividend Yield and Payout Ratio of N/A, the company does not currently distribute dividends to shareholders. Consequently, the firm retains its earnings to reinvest into its precision medicine and robotics operations rather than paying out cash dividends. The overall growth and income profile presents a picture of a revenue-expanding business with a leveraged capital structure that prioritizes operational reinvestment and balance sheet management over shareholder income distributions.